1. Farashi-Bonab S, Khansari N. Anticancer dendritic cell vaccines producing effective antitumor T-cell responses. Int J Vaccines Vaccin. 2017; 4(3): 00081.doi: 10.15406/ijvv.2017.04.00081
2. Dye ES. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector Tcells temporarily causes the destruction of already disseminated tumor cells. J Immunol. 1986; 136(4): 1510-1515.
3. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980; 151(1): 69-80. doi: 10.1084/jem.151.1.69
4. Dye ES, North RJ. Specificity of the T-cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukoc Biol. 1984; 36(1): 27-37. doi: 10.1002/jlb.36.1.27
5. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early stage cervical cancer. Cancer Res. 2007; 67(1): 354-361. doi: 10.1158/0008-5472.CAN-06-3388
6. Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumourinfltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003; 52(7): 423-428. doi: 10.1007/s00262-003-0388-5
7. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005; 437(7055): 141-146. doi: 10.1038/nature03954
8. Kline J, Brown IE, Zha YY, et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008; 14(10): 3156-3167. doi: 10.1158/1078- 0432.CCR-07-4696
9. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med. 1992; 175(1): 139-146.
10. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002; 3(11): 999-1005. doi: 10.1038%2Fni1102-999
11. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004; 22(6): 1136-1151. doi: 10.1200/JCO.2004.10.041
12. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007; 13(6): 1757-1761. doi: 10.1158/1078-0432.CCR-06-2599
13. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008; 111(6): 3220-3224. doi: 10.1182/blood-2007-05-085159
14. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T-cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8): 1537- 1544. doi: 10.1182/blood-2008-12-195792
15. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127): 127ra37. doi: 10.1126/scitranslmed.3003689
16. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443-2454. doi: 10.1056/NEJMoa1200690
17. Farashi-Bonab S, Khansari N. Regulatory T-cells in cancer patients and their roles in cancer development/progression. MOJ Immunol. 2014; 1(4): 00024. doi: 10.15406/moji.2014.01.00024
18. Farashi-Bonab S, Khansari N. Improving of antitumor immunity and therapeutic efficacy of cancer vaccines and adoptive immunotherapies using monoclonal antibodies. MOJ Immunol. 2015; 2(5): 00062. doi: 10.15406/moji.2015.02.00062
19. Farashi-Bonab S, Khansari N. Dendritic cell maturation is a critical step in dendritic cell vaccine preparation for cancer therapy. Vaccin Res Open J. 2016; 1(1): 25-32.
20. Punj V, Bhattacharyya S, Saint-Dic D, et al. Bacterial cupredoxinazurin as an inducer of apoptosis and regression in human breast cancer. Oncogene. 2004; 23(13): 2367-2378. doi: 10.1038/sj.onc.1207376
21. Cho JH, Lee MH, Cho YJ, et al. The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs. Yonsei Med J. 2011; 52(5): 773-778. doi: 10.3349/ymj.2011.52.5.773
22. Yamada T, Fialho AM, Punj V, et al. Internalization of bacterial redox protein azurin in mammalian cells: Entry domain and specificity. Cell Microbiol. 2005; 7(10): 1418-1431. doi: 10.1111/j.14625822.2005.00567.x
23. Yamada T, Goto M, Punj V, et al. The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53. Infect Immun. 2002; 70(12): 7054-7062. doi: 10.1128%2FIAI.70.12.7054-7062.2002
24. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: Clinical results. Adv Exp Med Biol. 2010; 667:111-123. doi: 10.1007/978-1-4419-1603-7_10
25. Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006; 116(7): 1946-1954. doi: 10.1172/JCI28045
26. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012; 18(3): 858-868. doi: 10.1158/1078-0432.CCR-11-2121
27. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116(2): 180-183. doi: 10.1016/s0022-5347(17)58737-6
28. Rayn KN, Hale GR, Grave GP, Agarwal PK. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018; 34(1): 11-19. doi: 10.4103%2Fiju.IJU_296_17
29. Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med. 1947; 66(2): 461-467. doi: 10.3181/00379727-66-16124
30. Malmgren RA, Flanigan CC. Localization of the vegetative form of clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res.1955; 15(7): 473-478.
31. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 2001; 66(2): 165-170. doi: 10.1023/a:1010644217648
32. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A. 2001; 98(26): 15155-15160. doi: 10.1073/pnas.251543698
33. Yu YA, Timiryasova T, Zhang Q, Beltz R, Szalay AA. Optical imaging: Bacteria, viruses, and mammalian cells encoding lightemitting proteins reveal the locations of primary tumors and metastases in animals. Anal Bioanal Chem. 2003; 377(6): 964-972. doi: 10.1007/s00216-003-2065-0
34. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nature Biotech. 2004; 22(3): 313-320. doi: 10.1038/nbt937
35. Yu YA, Zhang Q, Szalay AA. Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. Biotechnol Bioeng. 2008; 100(3): 567-578. doi: 10.1002/bit.21785
36. Stritzker J, Weibel S, Hill PJ, et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol. 2007; 297(3): 151-162. doi: 10.1016/j.ijmm.2007.01.008
37. Leschner S, Westphal K, Dietrich N, et al. Tumor invasion of Salmonella enteric serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One. 2009; 4(8): e6692. doi: 10.1371/journal.pone.0006692
38. Crull K, Bumann D, Weiss S. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol. 2011; 62(1): 75-83. doi: 10.1111/j.1574-695X.2011.00790.x
39. Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther. 2014; 39(8): 745-750. doi: 10.1111/apt.12655
40. Mughini-Gras L, Schaapveld M, Kramers J, et al. Increased colon cancer risk after severe Salmonella infection. PLoS One. 2018; 13(1): e0189721. doi: 10.1371/journal.pone.0189721
41. Crull K, Weiss S. Antibiotic control of tumor-colonizing Salmonella enterica serovar Typhimurium. Exp Biol Med (Maywood). 2011; 236(11): 1282-1290. doi: 10.1258/ebm.2011.011111
42. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo. Nat Biotechnol. 1999; 17(1): 37-41. doi: 10.1038/5205
43. Frahm M, Felgner S, Kocijancic D, et al. Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy. MBio. 2015; 6(2). pii:e00254- pii:e00315. doi: 10.1128/mBio.00254-15
44. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis. 2000; 181(6): 1996-2002. doi: 10.1086/315497
45. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA. 2005; 102(3): 755-760. doi: 10.1073/pnas.0408422102
46. Zhong Z, Kazmierczak RA, Dino A, et al. Salmonella-hosTcell interactions, changes in hosT-cell architecture, and destruction of prostate tumor cells with genetically altered Salmonella. Microsc Microanal. 2007; 13(5): 372-383. doi: 10.1017/S1431927607070833
47. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002; 20(1): 142-152. doi: 10.1200/JCO.2002.20.1.142
48. Toneri M, Miwa S, Zhang Y, et al. Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. Oncotarget. 2015; 6(31): 31335- 31343. doi: 10.18632/oncotarget.5866
49. Liu T, Chopra AK. An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4 T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther. 2010; 17(2): 97-108. doi: 10.1038/cgt.2009.58
50. Di Virgilio F. Purines, purinergic receptors, and cancer. Cancer Res. 2012; 72(21): 5441-5447. doi: 10.1158/0008-5472.CAN-12- 1600
51. Luo X, Li Z, Lin S, et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res. 2001; 12(11-12): 501-508. doi: 10.3727/096504001108747512
52. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother. 2002; 25(3): 218-225. doi: 10.1097%2F01.CJI.0000014623.45316.93
53. Fu W, Chu L, Han X, Liu X, Ren D. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dualapoptosis-related gene vector delivered by orally attenuated Salmonella enterica serovar typhimurium in murine tumor models. J Gene Med. 2008; 10(6): 690-701. doi: 10.1002/jgm.1191
54. Gentschev I, Fensterle J, Schmidt A, et al. Use of a recombinant Salmonella enterica serovar typhimurium strain expressing CRaf for protection against C-Raf induced lung adenoma in mice. BMC Cancer. 2005; 5: 15. doi: 10.1186/1471-2407-5-15
55. Fensterle J, Bergmann B, Yone CL, et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther. 2008; 15(2):85-93. doi: 10.1038/ sj.cgt.7701109
56. Avogadri F, Mittal D, Saccheri F, et al. Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immunol. 2008; 38(7): 1937-1947. doi: 10.1002/eji.200738035
57. Saccheri F, Pozzi C, Avogadri F, et al. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med. 2010; 2(44): 44ra57. doi: 10.1126/scitranslmed.3000739
58. Binder DC, Engels B, Arina A, et al. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T-cells to reject long-established cancer. Cancer Immunol Res. 2013; 1(2): 123-133. doi: 10.1158/2326-6066.CIR-13-0058
59. Yoon W, Yoo Y, Chae YS, Kee SH, Kim B. Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment. Ann Oncol. 2018; 29(9): 2010-2017. doi: 10.1093/annonc/mdy240
60. Monack DM, Raupach B, Hromockyj AE, Falkow S. Salmonella typhimurium invasion induces apoptosis in infected macrophages. Proc Natl Acad Sci U S A. 1996; 93(18): 9833-9838. doi: 10.1073/pnas.93.18.9833
61.Hersh D, Monack DM, Smith MR, et al. The Salmonella invasion SipB induces macrophage apoptosis by binding to caspase 1. Proc Natl Acad Sci USA. 1999; 96(5): 2396-2401.doi: 10.1073/ pnas.96.5.2396
62. Kim JM, Eckmann L, Savidge TC, et al. Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest. 1998; 10 2(10): 1815-1823. doi: 10.1172/JCI2466
63. Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009; 14(4): 364-375. doi: 10.1007/s10495-008-0303-9
64. Jang MJ, Kim JE, Chung YH, et al. Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimurium generate effective anti tumor immunity. Vaccine. 2011; 29(13): 2400-2410. doi: 10.1016/j.vaccine.2011.01.036
65. Hong EH, Chang SY, Lee BR, et al. Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. Vaccine. 2013; 31(10): 1377-1384. doi: 10.1016/j.vaccine.2013.01.006